Market capitalization | €8.78b |
Enterprise Value | €8.99b |
P/E (TTM) P/E ratio | 126.80 |
EV/FCF (TTM) EV/FCF | 20.54 |
EV/Sales (TTM) EV/Sales | 5.22 |
P/S ratio (TTM) P/S ratio | 5.10 |
P/B ratio (TTM) P/B ratio | 2.82 |
Dividend yield | 3.62% |
Last dividend (FY25) | €1.47 |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
21 Analysts have issued a Qiagen forecast:
21 Analysts have issued a Qiagen forecast:
Dec '24 |
+/-
%
|
||
Revenue | 1,723 1,723 |
1%
1%
|
|
Gross Profit | 1,099 1,099 |
2%
2%
|
|
EBITDA | 439 439 |
11%
11%
|
EBIT (Operating Income) EBIT | 431 431 |
11%
11%
|
Net Profit | 73 73 |
76%
76%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Head office | United States |
CEO | Thierry Bernard |
Employees | 5,232 |
Founded | 1996 |
Website | www.qiagen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.